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3Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, SwedenABSTRACT Uptake of copper (Cu) ions into human cells is mediated by the plasma membrane protein Ctr1 and is followed by
Cu transfer to cytoplasmic Cu chaperones for delivery to Cu-dependent enzymes. The C-terminal cytoplasmic tail of Ctr1 is a 13-
residue peptide harboring an HCH motif that is thought to interact with Cu. We here employ biophysical experiments under
anaerobic conditions in peptide models of the Ctr1 C-terminus to deduce Cu-binding residues, Cu affinity, and the ability to
release Cu to the cytoplasmic Cu chaperone Atox1. Based on NMR assignments and bicinchoninic acid competition experi-
ments, we demonstrate that Cu interacts in a 1:1 stoichiometry with the HCH motif with an affinity, KD, of ~10
14 M. Removing
either the Cys residue or the two His residues lowers the Cu-peptide affinity, but site specificity is retained. The C-terminal pep-
tide and Atox1 do not interact in solution in the absence of Cu. However, as directly demonstrated at the residue level via NMR
spectroscopy, Atox1 readily acquires Cu from the Cu-loaded peptide. We propose that Cu binding to the Ctr1 C-terminal tail
regulates Cu transport into the cytoplasm such that the metal ion is only released to high-affinity Cu chaperones.INTRODUCTIONCopper (Cu) ions act as essential cofactors in proteins that
facilitate cellular reactions such as respiration, antioxidant
defense, neurotransmitter biosynthesis, connective-tissue
biosynthesis, and pigment formation (1–3). Since free Cu
is toxic, the intracellular concentration of Cu is regulated
via dedicated proteins that facilitate its uptake, efflux, and
distribution to target Cu-dependent proteins and enzymes
(4–6). In human cells, Cu is translocated from the plasma
to the cytoplasm by the trimeric membrane-spanning pro-
tein Ctr1 (5,7,8).
Each Ctr1 polypeptide is 190 residues long. In the assem-
bled trimer, 67 of the amino acids in the N-terminus are
extracellular and the last ~13 residues in the C-terminus
are intracellular; the rest of the residues constitute three
transmembrane domains (9) (Fig. 1). Based on the 7 A˚
cryo-electron microscopy structure, the Ctr1 trimer contains
a narrow pore at the plasma membrane that widens into a
vestibule on the intracellular side (10). Although the N-ter-
minus is rich in Met and His residues, the membrane-span-
ning pore appears lined with Met triads that transiently
interact with Cu (11). It has been hypothesized that once
Cu has been transferred through the Ctr1 channel, a recip-
ient protein will bind Cu immediately. Recipient proteins
are thought to be the cytoplasmic Cu chaperones Atox1Submitted August 26, 2015, and accepted for publication November 10,
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0006-3495/16/01/0095/8and CCS, responsible for independent Cu transfer pathways
a) to the copper-transporting P1B-type ATPases ATP7A (i.e.,
Menke disease protein) and ATP7B (i.e., Wilson disease
protein) in the trans-Golgi network and b) to cytoplasmic
Cu, Zn superoxide dismutase (SOD1), respectively.
Since CCS possesses the capacity to interact with lipid bi-
layers, membrane scaffolding may be a mechanism that fa-
cilitates interactions between Ctr1 and cytoplasmic
chaperones (12). As an alternative to direct Ctr1-chaperone
interactions, it was proposed that glutathione may act as an
intermediate Cu-binding molecule bridging between Ctr1
and the cytoplasmic chaperones (13).
In yeast, Ctr1 has a cytosolic 125-residue C-terminal
domain with six cysteine residues that has been shown to
interact with the yeast Atox1 homolog, Atx1, and exchange
Cu (14,15). In contrast to yeast, in human Ctr1, the cyto-
plasmic C-terminus is only a short peptide that nonetheless
contains the putative metal-binding motif His-Cys-His
(HCH) (9). The HCH motif has been proposed to regulate
and/or restrict Ctr1-mediated Cu entry into the cytoplasm, as
mutation of this site in the full-length protein (HCH
substituted to AAA, or truncation of the C-terminus) substan-
tially increased the rate of Cu transport into human cells (16).
To directly address the Cu(I) binding capacity of the hu-
man Ctr1 C-terminus in vitro, we have here applied spectro-
scopic methods to a set of variant peptides at anaerobic
conditions (Fig. 1). The experiments performed demonstrate
that Cu(I) binds to the HCH motif, with all three residues
contributing to the interaction, and with an intermediate af-
finity that allows for efficient Cu transfer to the apo-form of
Atox1 in solution.http://dx.doi.org/10.1016/j.bpj.2015.11.016
FIGURE 1 Schematic model of a membrane-spanning Ctr1 monomer
with an extracellular N-terminus, three transmembrane domains, and the
C-terminal tail on the cytosolic side (red box). The C-terminal WT
sequence and the three variants are enlarged. Positions for alanine muta-
tions are highlighted in orange. Peptides are indicated by the abbreviations
used here (WT, HAH, ACA, and AAA). To see this figure in color, go
online.
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Materials, conditions, and sample preparations
Sample buffer was 30 mMMOPS with 50 mM sodium chloride at pH 7.5 in
all experiments unless otherwise stated. Four peptides (Fig. 1) were pur-
chased that consisted of the 13 most C-terminal amino acids of the human
Ctr1 polypeptide (GenScript USA, Piscataway, NJ). Peptide sequences
were KKAVVVDITEHCH (WT), KKAVVVDITEHAH (HAH variant),
KKAVVVDITEACA (ACA variant), and KKAVVVDITEAAA (AAA
variant) (mutations are underlined). Lyophilized peptides were dissolved
in degassed sample buffer and aliquoted under anaerobic conditions in a ni-
trogen-equilibrated glove box. All further preparation steps were performed
under anaerobic conditions as well. The stability of anaerobic conditions
was monitored via dithiothreitol (DTT) solutions stored for a couple of
days in the glove box. The concentration of nonoxidized thiols was deter-
mined by Ellman’s assay (see below) as a function of time in the glove
box. The concentrations of the peptide stocks were determined as
4.2 mM (for AAA) and 4.6 mM (for HAH) by amino acid analysis at the
Amino Acid Analysis Center, Uppsala University. For the cysteine-contain-
ing samples (WT and ACA variants), Ellman’s assay provided stock con-
centrations of 1.2 mM (for WT) and 3.0 mM (for ACA). A stock solution
of 1 M CuCl in 37% hydrochloric acid was anaerobically prepared and
stored. Further dilution steps with sample buffer were performed directly
before experiments. For determination of Cu(I) concentration, the bicincho-
ninic acid (BCA) assay (see below for details; measuring the absorbance at
a wavelength of 562 nm) was used. Solutions of different concentrations of
CuCl2 (10–200 mM) were reduced with 300 mMDTTand incubated for 2 h.
After addition of 25.7 mM BCA and 1 h incubation time, the absorbance
was measured and plotted against Cu(I) concentration. Competition be-
tween DTT and BCA was neglected due to the 100-fold higher concentra-
tion of BCA. A linear fit of the data points yielded an extinction coefficient
of ε562 ¼ 7100 cm1 M1 for the BCA2-Cu complex (Fig. S1 C in the Sup-
porting Material).
Using this reference experiment, the concentration of the CuCl stock so-
lution was controlled by mixing with 25.7 mM BCA and measuring absor-
bance before every single set of experiments. In addition, anaerobic titration
of 100 mMBCAwith Cu(I) confirmed the assumed Cu(I) concentration. As
expected, because of the 2:1 BCA/Cu complex stoichiometry, a linear in-
crease in absorption due to Cu(I) binding to BCA exhibited saturation at
half the BCA concentration (Fig. S1 A). Atox1 was expressed and purified
as previously reported (17,18). After the established purification procedure
including DTT-containing buffer, the protein sample was transferred to the
glove box and a buffer exchange was conducted on a desalting PD10 col-
umn (GE Healthcare, Little Chalfont, United Kingdom) with degassedBiophysical Journal 110(1) 95–102DTT-free sample buffer. The elution profile was analyzed for free thiols
with Ellman’s reagent, demonstrating a clear separation of the protein
from free DTT (Fig. S1 B). Both Ellman’s assay (determining the concen-
tration of free thiols of Atox1; see details below) and protein absorbance at
280 nm (ε280¼ 2980 cm1 M1) gave a concentration of 850 mM (53.5%)
for the Atox1 stock solution.Circular dichroism spectroscopy
A total volume of 1 mL of 100 mM peptide sample was prepared in a 1 cm
quartz cuvette (Hellma, Mu¨llheim, Germany) and titrated with 5 mM CuCl
solution in the glove box. Between each titration step the cuvette was sealed
with a vacuum grease-coated cap and circular dichroism (CD) and absorp-
tion spectra were measured outside the glove box.Ellman’s assay
5,50-dithiobis-(2-nitrobenzoic acid) (DTNB), or Ellman’s reagent, was pur-
chased from Sigma Aldrich (St. Louis, MO) and prepared as a 10 mM stock
solution in degassed sample buffer. For determination of free thiols, each
sample was mixed with DTNB and absorbance at 412 nm was measured.
For quantitative data analysis, reference absorbance values using known
concentrations of L-cysteine were determined. The reference line yielded
an extinction coefficient of ε412 ¼ 14,000 cm1 M1.BCA competition assay
BCA was purchased as ready-to-use reagent A of the BCA Protein Assay
Kit (Thermo Fisher Scientific, Waltham, MA). This stock solution of
25.7 mM BCA was degassed and transferred to the glove box. Further di-
lutions in sample buffer were performed anaerobically. For each data point
in the peptide titrations to BCA2-Cu, a 100 mL sample was prepared with
100 mM BCA, 44 mM CuCl, and peptide of different concentrations.
CuCl was always added as the last step, followed by incubation for 2 h
in the glove box before samples were transferred from the glove box to
the spectrophotometer. BCA2-Cu absorbance was measured at 562 nm (19).NMR spectroscopy
For NMR experiments, sealable NMR tubes (Hellma) were used. Total
volumes of 600 mL, including 25 mL D2O, were prepared anaerobically,
sealed, and transferred to the NMR spectrometer. All NMR experiments
were conducted at a Bruker Avance III HD 850 spectrometer equipped
with a TCI cryoprobe. The Ha-Ca correlations for the Ctr1 WT peptide
were assigned using two-dimensional (2D) homonuclear nuclear Over-
hauser effect spectroscopy and total correlation spectroscopy experiments
at T ¼ 288 K and a concentration of 1 mM. NMR diffusion experiments
were performed at T ¼ 298 K and a peptide concentration of 300 mM using
a pulse sequence comprising a stimulated echo assisted by bipolar gradi-
ents (20), G, employing a diffusion time, D, of 50 ms and gradient length,
d, of 6 ms along the z axis. Gradients were calibrated as described in Berger
and Braun (21). Integrals for proton signals, I, were determined in the spec-
tral range between 6 and 9 ppm and used for calculation of the diffusion
coefficient, D:
IðGÞ ¼ Ið0Þexp G2g2d2DðD d=3Þ;
where g is the gyromagnetic ratio. The Cu(I) interaction studies of WT,
HAH variant, and AAAvariants were performed at T ¼ 288 K at a concen-
tration of 120 mM (WT) and 350 mM (HAH and AAA), respectively. Cu(I)
was added from a stock solution of 10 mM CuCl to avoid dilution of the
peptide. The one-dimensional proton-observed titration of Cu(I) to HAH
variant was performed at T ¼288 K using an initial peptide concentration
Copper Binding to Ctr1 C-Terminus 97of 300 mM and stepwise additions of CuCl aliquots from a 10 mM stock.
Two-dimensional 1H-15N HSQC experiments were performed at T ¼
288 K using Atox1 concentrations of 100 mM (apo condition), 200 mM
(when Cu(I) was added), or 350 mM (when apo HAH variant or Cu-loaded
HAH variant was added). Additional interaction studies between Atox1 and
the WT peptide in the presence or absence of Cu(I) were conducted at T ¼
288 K at a Bruker Avance III HD 600 spectrometer equipped with a cryo-
genic BBO probe head. Sample concentrations were 60 mM (apo Atox1)
and 120 mM (apo WT peptide) in the absence of Cu(I) and, for Cu transfer
analysis, 175 mM (apo Atox1) and 350 mM WT peptide premixed with
175 mM Cu(I).RESULTS
Ctr1 C-terminal peptides bind Cu(I)
Laboratory experiments with Cu(I) pose the challenge to
keep the copper ions in the reduced state throughout the ex-
periments. Whereas many experiments with Cu chaperones
such as Atox1 and CCS can be performed under normal at-
mospherewith DTTas reducing agent (22–25), this approach
only works for proteins with high Cu(I) affinity. As DTT it-
self has high affinity for Cu(I) (dissociation constant,
KD ¼ 1015 M (26)), it can act as competitor to proteins
and peptides with lower or comparable Cu affinities. This
was noted for the Ctr1 C-terminal peptide in our first exper-
iments, where we used aerobic DTT conditions (data not
shown). In the presence of a fivefold excess of DTTover pep-
tide, therewas noCu binding detected to theWTCtr1 peptide
(by absorbance, CD, or NMR), implying that the peptide had
a Cu(I) affinity similar to or weaker than that of DTT.
To overcome this problem, we turned to a cleaner sample
preparation, without reducing agents, performed in a glove
box with an oxygen-free nitrogen atmosphere and degassed
buffers. Cuvettes and sample tubes for spectroscopic ana-
lyses were always filled inside the glove box and tightly
sealed, keeping oxygen-free conditions also outside the
glove box for the duration of the measurements. The latter
was confirmed with control experiments using vials of
DTT and CuCl sealed in the glove box but then stored
outside the glove box and tested for free thiols (DTNB)
and reduced Cu (BCA) as a function of time. For at least
2–3 days, there was no change in the spectroscopic values,
indicating that the conditions remained anaerobic during
this time frame. Nevertheless, as Cu(I) under neutral pH
tends to precipitate, copper solutions were always diluted
into sample buffer right before experiments.
For the WT Ctr1 peptide, CD spectra measured after
anaerobic titration with Cu(I) revealed spectral changes in
the 230–280 nm region (reporting on tertiary interactions
and Cu-Cys interactions), and absorption data exhibited
increased absorbance in the wavelength range 250–
350 nm. Both observations implied Cu(I) binding to the pep-
tide. The signal changes appeared to saturate when Cu(I)
was added in a 1:1 molar ratio, suggesting a 1:1 binding stoi-
chiometry (Fig. S2). Similar spectral changes were observed
upon titrating Cu(I) to the ACA variant (data not shown).Peptide affinities for Cu(I) through BCA
competition
To determine the affinities of the Ctr1 C-terminal peptides
(P) for binding of Cu(I) (metal ion, M) we used a competi-
tion assay (Eq. 1) with BCA as the competing chromophoric
ligand (L) for Cu(I).
PþML2/MPþ 2L: (1)
As the complex of two BCAmolecules with one Cu(I) ion
possesses a high absorption band at l ¼ 562 nm, changes in
the BCA2-Cu complex concentration due to competition
with another ligand (here, the different peptides) for Cu(I)
will be detectable by absorption changes. The principal
idea was introduced by Xiao et al. (19) and successfully
applied to various Cu(I)-binding proteins (26). Briefly,
BCA is loaded with Cu(I) in a BCA/Cu(I) molar ratio of
2.5 at anaerobic conditions. This ensures that all Cu(I)
ligand is found in the chromophoric 2:1 complex with
BCA, with negligible amounts of the 1:1 complex. The
Cu-loaded BCA is then titrated with the peptide of interest
(L in Eq. 1) while (through dilutions) keeping the concentra-
tions of Cu(I) and BCA constant. As addition of increasing
amounts of peptide will compete for Cu(I), the concentra-
tion of the chromophoric BCA2-Cu complex decreases.
The experimentally determined decrease in absorbance at
l ¼ 562 nm is plotted against the ratio of peptide to
Cu(I). Equation 2 can be used to fit the experimental data:
KDb2 ¼
½Ptotal
½MP1
½Ltotal
½ML2
 22½ML2
; (2)
with [L]total for concentration of BCA and [P]total for the
peptide concentration. [MP] and [ML2] are calculated on
the basis of absorbance changes normalized to the values
without peptide (index 0):
½MP ¼ ½Mð1 abs562=abs562;0Þ (3)
½ML2 ¼ ½Mðabs562=abs562;0Þ: (4)To derive the dissociation constant, KD, for each Cu-pep-
tide complex, we used the carefully determined value of
b2 ¼ 1017.2 M2 as the formation constant for the copper
complex with BCA, BCA2-Cu (26). Titration data for the
four peptides to BCA2-Cu at anaerobic conditions with
accompanying fits to Eq. 2 are shown in Fig. 2, and KD
values are reported in Table 1. (We note that there are devi-
ations between the experimental data points and two of the
fits at low Ctr1 peptide concentrations.)
Whereas the WT peptide competes efficiently with BCA
for Cu(I), as visualized by the decreasing absorbance values
in the titration, this effect is dramatically attenuated for all
three peptide variants with the HCH motif perturbed, andBiophysical Journal 110(1) 95–102
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FIGURE 2 Anaerobic BCA2-Cu competition assay providing Cu(I) af-
finities for WT peptide (red circles) and peptide variants, HAH (green
squares), ACA (blue triangles), and AAA (yellow double triangles).
Each sample was prepared anaerobically and Cu(I) was added last, followed
by incubation for 2 h before absorption measurements at 562 nm. The
whole process was performed at strict anaerobic conditions. Absorbance
values were normalized to the value measured for the solution without pep-
tide addition. Results for the best fits of Eq. 2 to the experimental data sets
are shown as colored curves (corresponding KD values are reported in Table
1). To see this figure in color, go online.
98 Kahra et al.for the AAA peptide, there is in essence no change. For WT,
a dissociation constant of KD ¼ (2.35 0.2)  1014 M was
determined (Table 1). Exchange of the two His to Ala (ACA
variant) caused a 45-fold loss in affinity, whereas exchange
of the Cys for Ala (HAH variant) decreased the affinity
more than two orders of magnitude compared to WT
(Table 1). For the AAA variant, because of the small
changes in absorption, no affinity value was determined;
instead, we concluded that the affinity of this peptide for
Cu must be dramatically weaker than for the other peptides.NMR analysis of Cu(I) binding
The NMR diffusion profile for the WT peptide (Fig. S3) cor-
responds to a diffusion coefficient of D ¼ (1.965 0.01) 
1010 m2 s1, which can be translated to a hydrodynamic
radius, rH, of 11.1 A˚ by using the Stokes-Einstein relation-
ship. In accord with a monomeric state, a rough estimation
of rH for an unstructured peptide of 13 residues yields an rHTABLE 1 Cu(I) Dissociation Constants
Peptide Variant KD (10
14 M)
WT 2.35 0.2
HAH 4005 30
ACA 905 10
AAA ND
Equation 2 was fitted to the experimental data (Fig. 2) with substitution of
Eqs. 3 and 4 using b2 ¼ 1017.2 M2 as the Cu-BCA2 complex formation
constant. ND, not determined.
Biophysical Journal 110(1) 95–102of 9.5 A˚ (27). For comparison, an unstructured trimer
(39 residues) would correspond to an rH of 17.8 A˚ (27).
One-dimensional NMR was used to confirm Cu(I) inter-
action with WT and HAH peptides. Cu(I) titration to the
HAH variant while monitoring the amide proton signals is
shown in Fig. S4. The NMR data demonstrate that there
are Cu(I)-peptide interactions, in accord with the data ob-
tained using CD and absorption spectroscopy.
Upon assignments of NMR chemical shifts, residue-spe-
cific information on where the copper ion interacts can be
obtained. By employing 1H-13C HSQC analysis of Ha-Ca
correlations, 12 residues of the WT peptide could be as-
signed by homonuclear 1H-1H nuclear Overhauser effect
spectroscopy, 1H-1H total correlation spectroscopy, and het-
eronuclear 1H-13C HSQC experiments (with Lys1 missing;
see Table S1 for NMR assignments). Comparison of
1H-13C HSQC spectra for WT and the HAH variants re-
vealed that chemical-shift changes occurred only close to
the mutation site (Cys12) of the HAH variant as compared
to WT (Fig. 3).
Loss of Ha-Ca signal intensities at the C-terminus of the
WT peptide was found upon addition of Cu(I) (Fig. 4 A).
Also, loss of signal intensities and changes of chemical
shifts were found at the C-terminus of the HAH variant
upon addition of Cu(I) (Fig. 4 B). Generally, an interaction
may induce 1) a shift of cross signals (fast exchange on the
NMR timescale), 2) line broadening of signals (intermediate
exchange on the NMR timescale), or 3) a decrease of orig-
inal peaks and an increase in new peaks (slow exchange on
the NMR timescale). Because we observe mostly intensity
decreases, along with some broadening, the collected data
suggest that Cu(I) interacts with the Ctr1 C-terminus on
the slow to intermediate NMR timescale.
In Fig. 5, the intensity decreases of Ha-Ca correlations
for the Cu-loaded WT (Fig. 5 A) and the HAH variant
(Fig. 5 B) compared to the apo form are plotted as a function
of peptide sequence. The data reveal that Cu(I) binds at theFIGURE 3 Comparison of 1H-13C HSQC spectra for Ha-Ca correlations
for the WT peptide (black) and the HAH variant (red). Assignments of the
residues in the WT (black) are shown using the single-letter amino acid
code. The Ha-Ca correlation for Ala12 of the HAH variant is shown in
red. To see this figure in color, go online.
AB
FIGURE 4 (A) Impact of Cu(I) addition to Ha-Ca correlations of the WT
peptide (apo, black; Cu(I)-loaded (holo), red). Cu(I) was added in an equal
molar amount, and noise signals of the holo state are indicated by asterisks.
(B) Impact of Cu(I) addition to Ha-Ca correlations of the HAH peptide
(apo, black; holo, red). Cu(I) was added in an equal molar amount and as-
signments for the apo state variant are shown. To see this figure in color, go
online.
Copper Binding to Ctr1 C-Terminus 99C-terminal residues in both peptide variants. For WT, the
highest-intensity attenuation is for Cys12 and His13, whereas
upon Cys to Ala mutation, the Cu(I) interaction affects peak1.0
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FIGURE 5 (A) Intensity decrease of the Ha-Ca correlations of Cu(I)-
loaded WT peptide relative to the apo form of WT. Missing assignment
of Lys1 is marked by an asterisk. (B) Intensity decrease of Ha-Ca correla-
tions of Cu(I)-loaded HAH variant relative to the apo form of HAH.
Missing assignment of Lys1 is marked by an asterisk.intensity all the way from His13 to Glu10, which may imply
that Cu(I) utilizes the glutamic acid as a substitute of the
removed Cys12. However, since such a side effect is also
found for Cu(I) interaction with wild-type Ctr1 (decreased
intensity of Thr9 and Glu10), we speculate that this is an in-
direct effect of nearby Cu(I) coordination. As an important
note, amide proton signals of peptides are generally highly
sensitive to exchange with the solvent. Consequently, non-
exchangeable signals (such as the Ha-Ca correlations
used here) should be used for quantitative analysis.
The assignment of Ha-Ca correlations for Ctr1 WT
cannot be directly transferred to the AAA variant, as the
presence of three mutations strongly changes the chemical
shifts in the 2D 1H-13C HSQC spectrum (Ala11-Ala13 chem-
ical shifts are ambiguous; Table S1 and Fig. S5 A). Nonethe-
less, spectral analysis yields only a weak response upon
Cu(I) addition to the AAA variant, showing signal loss of
only two chemical shifts (i.e., Lys2 and one of three ambig-
uous Ala residues; Fig. S5 B). Thus, in agreement with the
BCA competition experiments, the AAA variant does not
appear to have specific affinity for Cu(I) above that
involving weak nonspecific interactions. Because of poor
solubility, we could not perform corresponding NMR exper-
iments with the ACA peptide.Cu-mediated peptide interaction with Atox1
We selected the HAH variant for subsequent 13C-based
NMR experiments in the presence of Atox1, because the
observed perturbations of Ha-Ca correlations (chemical
shifts and signal intensities) in the 2D 1H-13C HSQC upon
Cu(I) addition were more pronounced for the HAH variant
than for the WT peptide.
Atox1 does not interact with the HAH variant in the
absence of Cu(I) when analyzed via the peptide Ha-Ca
chemical shifts (Fig. 6 A). In contrast, addition of Atox1
to the Cu(I)-loaded Ctr1 HAH variant results in Ha-Ca cor-
relations identical to those seen for the apo state of the HAH
variant (Fig. 6 B). This implies that Atox1 takes the Cu ion
from the metal-loaded peptide, based on observations via
the peptide signals.
The above reaction was also probed from the other side,
i.e., by monitoring the status of Atox1 using 15N-labeled
Atox1. Again, the HAH peptide did not interact with
Atox1 when probed via the Atox1 chemical shifts (Fig. 7
A). When Atox1 is loaded with Cu(I), there are loss of sig-
nals and changes of chemical shifts in the HSQC spectrum
of Atox1, as previously reported (28) (Fig. 7 B). Upon addi-
tion of Cu(I)-loaded HAH peptide to the apo form of Atox1,
the backbone signals alter such that they now match the
spectrum for Cu(I)-loaded Atox1 (Fig. 7 C). The data imply
that the Cu(I) ion is transferred completely from the peptide
to Atox1, which is in accord with the much higher affinity of
Cu(I) for Atox1 (26) than for the HAH peptide (Table 1).
When we repeated the 1H-15N HSQC experiments withBiophysical Journal 110(1) 95–102
BA
FIGURE 6 (A) Comparison of 1H-13C HSQC spectra for Ha-Ca correla-
tions between the HAH variant (black) and the HAH variant mixed with an
equal molar amount of Atox1 (red). No Cu(I) is present. (B) Comparison of
1H-13C HSQC spectra for Ha-Ca correlations between the apo form of the
HAH variant (blue), the Cu(I) loaded form of the HAH variant (black), and
the Cu(I)-loaded form of HAH mixed with one equivalent of the apo form
of Atox1 (red). To see this figure in color, go online.
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FIGURE 7 (A) Comparison of 1H-15N HSQC spectra between Atox1
(black) and Atox1 titrated with an equal amount of the HAH peptide
(red); no Cu(I) is present. (B) Impact of Cu binding on the Atox1 1H-15N
HSQC spectrum (apo, black; Cu-loaded (holo) state, red). (C) Comparison
100 Kahra et al.the WT peptide and 15N-labeled Atox1, as expected, the
same result of complete Cu(I) transfer from the Ctr1 peptide
to Atox1 was found (Fig. S6, A and B).of 1H-15N HSQC spectra for Cu(I)-loaded Atox1 (black) and Atox1 after
the addition of an equal amount of Cu(I)-loaded HAH peptide (red). To
see this figure in color, go online.DISCUSSION
How Cu is internalized into cells by the trimeric membrane-
spanning protein Ctr1 is not fully elucidated. It is believed
that oxidized Cu ions are reduced extracellularly, perhaps
upon binding to histidine- and methionine-rich Cu-binding
sites in the extracellular Ctr1 N-terminal part, followed by
shuttling of the reduced metal ion through the internal
pore of the Ctr1 trimer, which is lined with methionine tri-
ads (5,7,8). It is proposed that the last stop for Cu in Ctr1
is the cytoplasmic C-terminus, which contains a putative
Cu-binding site in the form of an HCH motif. Because Cu
uptake rates by Ctr1 are increased when the C-terminus is
mutated (i.e., HCH exchanged to AAA) or truncated (16),
it appears that Cu binding to this site regulates Cu uptake
into cells, perhaps acting as an open/closed switch of the in-
ternal pore. One may speculate that Cu(I) binding to the
C-terminal site allosterically blocks further Cu(I) import
such that a new Cu ion cannot be channeled through Ctr1
from the extracellular space until the metal ion at the
HCH motif has been released.
The subsequent question is what biomolecule(s) obtains
Cu(I) from the Ctr1 C-terminal site. There are no free CuBiophysical Journal 110(1) 95–102ions in the cytoplasm, and instead, in essence, all Cu ions
present in the cytoplasm are bound either to proteins or to
small chelating agents (4–6). The most obvious candidates
to receive Cu(I) from Ctr1 are the various cytoplasmic Cu
chaperones (CCS and Atox1, as well as the Cu chaperone
providing Cu to the mitochondria, Cox17), but the reducing
agent glutathione is a possible candidate as well, as its con-
centration in the cytoplasm is high (13). In the case of CCS,
it was demonstrated in vitro that both CCS and its target Cu-
dependent enzyme, SOD1, could interact with artificial
membranes, and Ctr1 was found capable of delivering Cu
to CCS at these membranes, although no mechanistic
insight was provided (12).
Accurate estimations of protein affinities for Cu(I) are
difficult, and reported values for the same or similar proteins
are scattered, likely because of different experimental ap-
proaches with different ligand probes and affinity standards.
In a thorough study aiming to unify Cu(I)-binding affinities
of metal chaperones, the Cu(I) affinity, KD, for Atox1 was
determined to be 1017.4 M at pH 7 (19,26). We used the
Copper Binding to Ctr1 C-Terminus 101same approach and affinity standards here and found a Cu(I)
affinity of ~1014 M for the HCH-containing peptide at
anaerobic conditions. Regardless of error bars, the peptide
affinity is clearly much lower (i.e., three orders of magni-
tude) than the Atox1 affinity for Cu(I), which agrees with
the observation of 100% transfer of Cu from the peptide
upon mixing with apo-Atox1 at stoichiometric concentra-
tions. Glutathione exists in high concentrations in the cyto-
plasm (1–10 mM) and may act as a competitor in terms of
Cu(I) binding in vivo (26); moreover, parameters such as ki-
netics and localization may overrule equilibrium thermody-
namics in vivo.
We want to emphasize that Cu exchange between the Ctr1
C-terminal peptide and Atox1 cannot proceed via metal
release from the peptide followed by free metal uptake by
Atox1 with a peptide affinity for Cu(I) of 1014 M. This
implies that even for the fastest on-rate constant ofCu(I) bind-
ing (assuming that diffusion controlled, kon ~ 10
8 M1 s1),
Cu(I) dissociation from the peptide would take at least 24 h
(1/koff). Therefore, the only way to transport the metal to
another partner within the time frame of the experiment is
via direct peptide-protein interaction. This mechanism ap-
pears common among the copper transport systems (29–32)
and has been elucidated in detail for Atox1 delivering Cu(I)
to the fourth metal-binding domain of ATP7B (22).
It appears that both the cysteine and the histidine residues
contribute to Cu(I) interaction with the peptide. Cysteine
sulfurs are often found as Cu(I) ligands in proteins, as is
the case in Atox1 and other Cu chaperones. In contrast, his-
tidine side chains are more often found in metal sites inter-
acting with Cu(II). Nonetheless, linear Cu(I) binding
involving two histidine imidazole rings have been reported
in a dipeptide system (33). We found that removing either
the cysteine or the two histidines in the Ctr1 peptide lowered
the affinity by ~200- and 45-fold, respectively. Thus, the ef-
fect is fivefold larger upon removing the cysteine versus the
two histidines, implying that the cysteine bond dominates.
Although the cysteine or histidine residues can be removed
with retention of Cu-binding-site specificity, removing the
complete HCH site appeared to abolish specific Cu(I) bind-
ing to the peptide. This result agrees with the previous
finding of Cu uptake rates into cells being affected by
both Ctr1 C-terminal truncation and HCH exchange to
AAA (16).CONCLUSION
We here show that Cu(I) at anaerobic conditions, mimicking
cytoplasmic conditions, interacts with all three residues in
the HCH motif in the Ctr1 C-terminus, resulting in a Cu-
peptide affinity that is higher than that of Cu-glutathione
but low enough to allow for efficient transfer of the metal
to the high-affinity cytoplasmic Cu chaperone Atox1. We
propose that direct delivery of Cu, via Cu-mediated transient
interactions between the C-terminal peptide and a Cu chap-erone such as Atox1, is a mechanism that facilitates control
of intracellular Cu levels (that matches the need of the cyto-
plasmic chaperones) and specificity of targets (avoiding un-
wanted and harmful Cu interactions with other cellular
components). Thus, the Cu transfer mechanism from the
C-terminal peptide of human Ctr1 to Atox1 appears analo-
gous to the yeast homologs, although the yeast Ctr1
C-terminus is a folded domain (125 residues) and harbors
a different metal site (14).SUPPORTING MATERIAL
Six figures and one table are available at http://www.biophysj.org/biophysj/
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